Global Hepatocyte Growth Factors (HGFs) Market Size Study, by Type (Phase III (Ongoing), Phase II (Approved), Phase II (Ongoing), Phase I, Preclinical) by Application (Oncology, Cardiovascular, Central Nervous System, Hematological Disorders) by End-User

Global Hepatocyte Growth Factors (HGFs) Market Size Study, by Type (Phase III (Ongoing), Phase II (Approved), Phase II (Ongoing), Phase I, Preclinical) by Application (Oncology, Cardiovascular, Central Nervous System, Hematological Disorders) by End-User (Pharmaceutical and Biotechnology Companies, CMOs & CDMOs, Research Centers & Academic Institutes) and Regional Forecasts 2022-2032

Global Hepatocyte Growth Factors (HGFs) market is valued at approximately USD 70.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2024-2032. Hepatocyte Growth Factors (HGFs) are potent mitogens for hepatocytes and various other cells including keratinocytes, melanocytes, epithelial, and endothelial cells. HGFs act as ligands for receptors encoded by the c-met proto-oncogene. The growth factors are crucial for diverse applications such as bioprocessing, cell culture, and regenerative medicine. These factors stimulate and regulate cellular activities, ensuring the viability and optimal growth of cells used in biopharmaceutical production. Producing high-quality recombinant growth factors is expensive, limiting their accessibility. Additionally, the short shelf life poses challenges in transportation, storage, and product viability, which may restrain the industry. However, the market is set to grow due to an exponential rise in liver illnesses and the increasing number of surgical operations that necessitate the use of HGFs for efficient and speedy wound healing.

Companies in the hepatocyte growth factors market are expanding their reach to unexplored economies in Asia Pacific, Latin America, and the Middle East & Africa to create awareness about these growth factors and prevent complications from inappropriately managed post-surgical operations.

Hepatocyte Growth Factor (HGF) is essential for liver regeneration as it promotes the growth of liver stem cells through signaling pathways that facilitate hepatic tissue healing, including collagen deposition. This process creates an environment conducive to the growth and expansion of progenitor cells. The International Journal of Pharmaceutical Chemistry and Analysis attributes 4% of global fatalities to liver disease, highlighting the critical need for proper healing of liver illnesses, thereby catalyzing the HGF market. Hepatocyte growth factor (HGF) regulates cell growth, morphogenesis, and cell motility in various cells, promoting neovascularization and epithelial repair during wound healing. HGFs act as hormone-like molecules that interact with exclusive cell surface receptors to control tissue repair. Despite being present in nanograms, they significantly influence wound repair and healing. With over 310 million major surgeries performed annually, according to the National Institutes of Health, HGFs are vital for post-surgical wound healing, expanding the market size.

North America dominated the hepatocyte growth factors market in 2023 and is expected to maintain its dominance during the forecast period, attributed to significant R&D investments by pharmaceutical companies, biotech firms, and research institutions in the U.S. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period. Asia Pacific's notable market growth is driven by Japan's advanced healthcare infrastructure and matured biopharmaceutical industry, along with extensive R&D in China.

Major market players included in this report are:

AVEO Pharmaceuticals, Inc.

Molecular Partners AG

YooYoung Pharmaceutical Co., Ltd.

F-star Therapeutics Inc.

Galaxy Bio Tech

Kringle Pharma

Novo Nordisk

Bristol-Myers Squibb

AstraZeneca

Merck & Co., Inc.

Gilead Sciences, Inc.

Sanofi SE

ViroMed

AnGes, Inc.

M3 Biotechnology, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:
• Phase III (Ongoing)
• Phase II (Approved)
• Phase II (Ongoing)
• Phase I
• Preclinical

By Application:
• Oncology
• Cardiovascular
• Central Nervous System
• Hematological Disorders

By End-User:
• Pharmaceutical and Biotechnology Companies
• CMOs & CDMOs
• Research Centers & Academic Institutes

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.